Research & Development: Page 100
-
PharmaVoice Team/PharmaVoice
Cover
On the Cover The Business of R&D Metrics Unlock Innovation with Marh Ahn Venture Capital Environment March 2005 www.pharmavoice.com Volume 5 Number 3 The Forum for the Industry Executive PharmaVOICE Download PDF
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
On the Calendar
February 15-17 WCBF Six Sigma in Chemicals & Pharmaceuticals Hyatt Regency Dallas, Dallas For more information, contact Louise Gosling, WCBF Six Sigma Solutions, at 44-14-83 76-0883, e-mail [email protected], or visit wcbf.com. February 15-18 18th Annual DIA Electronic Document Manageme...
By PharmaVoice Team • Jan. 2, 2008 -
Explore the Trendline➔
Getty Images
TrendlineOncology R&D
Cancer research remains a prime focus for the industry and often leads to pharma’s most impactful breakthroughs.
By PharmaVoice staff -
PharmaVoice Team/PharmaVoice
Drug Development
Drug Development Strong Clinical-Trial Management Systems Market Offers Opportunities for suppliers, Clinical Sponsors, and CROs Alike The U.S. clinical-trial management systems (CTMS) market is poised for steady growth through 2008, achieving a five-year compound annual growth rate (CAGR) of abo...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Financing
Kolodny-Hirsch. As a long-time participant in this industry, it is certainly encouraging to finally see that more biotech companies are on the verge of profitability. Nonetheless, there are still hundreds of private and publicly traded biotech firms that are in the red and struggling to survive. ...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
CDISC Study Data Tabulation Model
CDISC Study Data Tabulation Model B. Thompson. We are carefully reviewing the new Study Data Tabulation Model (SDTM) to ensure that our company is doing everything possible to streamline submissions of data to the agency. It should be a goal of companies and the agency to find and implement great...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Importation/Price Controls
Importation/Price Controls Nash-Wong. Pharmaceutical price differential in the international markets will be top of mind. So extreme it’s been called a trade deficit; the U.S. market is currently carrying the cost of R&D for the world. This price differential is just adding fuel to the pharma...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Patient Safety
Patient Safety Barrett. Patient safety is a cornerstone of clinical trials. But with the increasing pace of trials, it’s no longer efficient to be reactive; proactive, real-time monitoring can increase the safety of those participating in trials, spotting potential interactions, and flagging comm...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Cover
PharmaVOICE The Forum for the Industry Executive Year In Preview: 2005 More than 100 experts talk about the industry’s future www.pharmavoice.com December 2004 Special Issue Volume 4 Number 12 Download PDF
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Table of Contents
Contents Kristine Nash-Wong, Marketing Manager at HealthMedia, speaks about reputation enhancement. Dr. Thomas Wicks, VP of Regulatory Affairs at Odyssey Pharmaceuticals, talks about continuing treatment innovation while limiting costs. Scott Szwast, Sector Marketing Manager at UPS Supply Chain S...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Letter from the Editor
2005 Year In Preview Taren Grom In keeping with PharmaVOICE’s mission of providing insightful and provocative commentary on the business practices, strategies, and services that affect the life cycle of products from molecule through market, it is our pleasure to publish the first annual Year in ...
By Taren Grom • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Introduction
The Pulse of the Industry By Taren Grom This first annual PharmaVOICE Year in PreVIEW is designed to provide an overview of the challenges and trends expected to impact the life-sciences industry in the coming year and beyond. For this special forum, a distinguished list of more than 100 industry...
By Taren Grom • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Business Models
Turett. The pharmaceutical industry needs to resolve multiple bipolarities: being a business and being a public utility; being doctor-focused and being consumer-focused; and being about medical innovation and being about marketing. The industry has begun a process of self-reinvention that in 2005...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Medical Education
Medical Education Nash-Wong. Last year’s predictions on regulatory changes had us believing medical education was a thing of the past. Not so, if one considers the fact that physicians continue to attend educational meetings, despite limited food budgets and a ban on spouses. So rather than forec...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Multifunctional Teams
Multifunctional Teams Wilson. Historically, the pharmaceutical industry has faced two hurdles: achieving product registration and securing reimbursement. Today, demonstrating product value is becoming a much stronger issue. It’s not just a matter of product price, but the impact on total cost of ...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Technology
Technology Cauwenbergh. Ideally, predictive tools, including assays, computer modeling techniques, and biomarkers could shorten development time, reduce the cost of development, and increase the accuracy of diagnosis, making sure that the right patient gets the right drug because of proper diagno...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Risk Management
Risk Management Turett. The term risk management implies a defensive, prepare-for-the-worst strategy. While defensive preparation is certainly important, taking a fresh look at conducting business in a “patient-first” manner will reduce the need to implement a defensive approach. In other words, ...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Innovation
Innovation Drakeman. The engine that drives growth in the pharmaceutical industry is the discovery of new medicines for unmet medical needs. Much of the innovation in development now resides in the biotech sector. The challenge is to find the most efficient and productive ways to combine biotech’...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
PharmaTrax
Sales, Marketing, and R&D Trends from Industry Analysts Pharmaceutical Companies Rethink Consumer Marketing Strategies in 2005 Facing increased scrutiny from the federal government and the public, pharmaceutical companies are looking beyond direct-to-consumer (DTC) marketing to more effective...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
E-Media
ISB and IBM launch Human Proteome Folding Project on World Community Grid The Institute for Systems Biology (ISB), in partnership with IBM, United Devices, and the University of Washington, has launched the Human Proteome Folding Project on World Community Grid. This project, the first to run on ...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
What's New
HMP Launches Arthritis Practitioner HMP Communications is launching Arthritis Practitioner in May 2005. The publication will have editions in July, September, and November. The journal’s audience is comprised of more than 32,000 nurse practitioners and physician assistants that are profiled as hi...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
What's on Your Mind -- Opinions
Opinions Leadership Development In demanding times, leadership is a competitive edge. Good leaders provide opportunities for others to grow their communication, decision-making, problem-solving, and other related skills. Leading is setting direction and guiding others to follow that direction. Go...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Letter from the Editor
Letter from the Editor The Art of Communicating The popular Verizon ad, “Can you hear me now?” sums up one of the major roadblocks in any business partnership or relationship: miscommunication. No matter the relationship — client/provider, team/team, or person/person — the inability to clearly co...
By Taren Grom • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
Technology's Impact on Business Processes
Phil Garland It is not enough to simply implement technology. Companies are going to have to change the way they do business. Bill Stevens Technology is an enabling component of the entire business. If the people within the business do not have the right information to act on a daily basis then a...
By Denise Myshko • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
E-Media
Teranode Releases Life-Sciences R&D Platform, Pathway Analytics Solution Teranode Corp. has released Teranode Design Suite 2.5 (TDS 2.5), an enhanced, closed-loop R&D platform used to integrate modeling into existing informatics infrastructures. The platform improves research productivity...
By PharmaVoice Team • Jan. 2, 2008 -
PharmaVoice Team/PharmaVoice
PharmaOutlet
Contributed by Norman M. Goldfarb The Worst Informed Consent Ever: How Physicians Can Coerce and Unduly Influence Patients Informed consent requires that the potential subject be fully informed and capable of making a rational decision to participate in a clinical study. The attempt to incorporat...
By PharmaVoice Team • Jan. 2, 2008
Previous
